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Abstract
Background: The purpose of this retrospective analysis is to analyze clinical outcome, visual acuity and enucleation
rates after linear accelerator-based stereotactic fractionated photon radiotherapy for primary uveal melanoma.
Methods: Twenty-four patients with primary uveal melanoma treated at the Department of Radiation and
Oncology of the University Hospital Heidelberg between 1991 and 2015 were analyzed regarding survival and
treatment-related toxicity including eye- and sight-preservation.
Results: Photon radiotherapy (RT) offered good overall local control rates with a local progression-free survival
(LPFS) of 82% after 5 years and a median LPFS of 5.5 years at a median follow-up time of 5.2 years. Gender had a
significant impact on LPFS yielding a mean LPFS of 8.1 years for women and 8.7 years for men (p = 0.04). Of all local
progressions, 80% occurred within the first 5 years after RT. In one case, enucleation as final therapy option was
necessary. Enucleation-free survival (EFS) was related to the radiotherapy dose (p < 0.0001). Thus, higher prescribed
doses led to a significantly higher enucleation rate. T-stage had no significant impact on EFS, but affected the
enucleation rate (p = 0.01). The overall survival (OS) rate was 100% after 2 years and 70% after 5 years with a median
OS of 5.75 years. Age (p = 0.046), T stage (p = 0.019), local control rate (p = 0.041) and the time between diagnosis
and the first radiation session (p = 0.01) had a significant effect on OS. Applied biologically effective dose (BED) did
not significantly influence OS or PFS. A 2-year sight preservation rate of 75% could be achieved. In all patients,
irradiation could be applied safely without any interruptions due to side effects. Six significant late toxicities with
consequential blindness could be observed, making a secondary enucleation necessary in four patients. An impairment
of visual acuity due to chronic optic nerve atrophy was identified in five patients within 2 years after treatment.
Conclusions: Linear accelerator-based stereotactic fractionated photon radiotherapy is an effective method in the
treatment of uveal melanoma with excellent local control rates and a 2-year vision retention rate comparable to
brachytherapy (BRT) or proton beam radiotherapy, even available in small centers and easy to implement.
Interdisciplinary decision making is necessary to guarantee best treatment for every patient.
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Background
Uveal melanoma is a rare malignancy with an incidence of
six cases per million population in Europe each year, but it is
the most common non-cutaneous melanoma [1, 2]. It occurs
primarily in elderly men between 60 and 80 years [2]. The
role of sunlight and other environmental exposures have
been discussed in the literature, but their influence on the
pathogenesis is still unknown. For a long time, resection of
the tumor with a consecutive enucleation represented the
standard of therapy. Over the last four decades RT has be-
come more significant in the treatment of uveal melanoma;
not only in the combination with surgery but also as primary
treatment. Eye-preserving treatment with RT, especially in
the form of brachytherapy (BRT) or proton beam RT, has
shown promising results. The Collaborative Ocular Melan-
oma Study (COMS), a multicenter randomized trial, found
no difference in the 5-year overall survival rates of enucle-
ation or BRT in the treatment of small-size or medium-size
choroidal melanoma and established the role of BRT in the
treatment of uveal melanoma [3–5]. Nevertheless, the visual
acuity was impaired in 43% of the cases. Modern RT tech-
niques such as stereotactic RT or proton beam RT promise a
better preservation of organs at risk, especially in the therapy
of large and peripapillary tumors [6–8].
The aim of this retrospective study is to analyze the
value of a fractionated photon RT as eye-preserving treat-
ment and to determine prognostic factors for EFS. Fur-
thermore, negative side effects were compared to other
radiotherapy modalities described in the literature. For
this purpose, we have systematically analyzed clinical out-
comes like enucleation rates due to radiation-induced ret-
inopathy, toxicity and preservation of vision.
Methods
Patients who underwent treatment with linear
accelerator-based stereotactic fractionated and hypofrac-
tionated photon RT for uveal melanoma at the Depart-
ment of Radiation and Oncology of the University
Hospital Heidelberg between the years of 1991 to 2015
were included in this analysis; including melanomas of
the iris, ciliary body and choroid. Other tumor locations
in the orbital cavity as well as other tumor entities were
excluded. All patients received primary RT. Two patients
were treated with re-irradiation after previous radiother-
apy. At the time of the first diagnosis, all patients were
examined by an ophthalmologist. Ocular ultrasonog-
raphy, computed tomography (CT) and magnetic reson-
ance imaging (MRI) were performed to determine tumor
stage based on the 2010 American Joint Committee on
Cancer (AJCC) TNM (T = tumor, N = lymph node, M =
metastasis) classification for uveal melanoma [9] and to
exclude distant metastases at the time of the diagnosis.
After the treatment, tumor control was assessed every
3 months during the first year, every 6 months during
the second year, and subsequently once a year with an
ocular examination by the referring ophthalmologist.
Therapy was planned based on a CT scan in irradiation
position. For the immobilization of the patients, a
scotch-cast mask was used. To determine the target volume,
we used a current MRI scan for better demarcation. If a
current MRI scan was not available, we performed a CT
scan with a contrast agent for matching. Fractionation
schedules and prescription doses differed substantially, thus
we calculated the biologically equivalent dose (BED) with a
tumor α/β of 10 for each patient for better comparability.
Radiotherapy was performed in all patients in a stereotactic
set-up applying the prescribed dose to the 80% isodose line.
All statistical analyses were performed with IBM SPSS
Statistics version 24. Primary endpoints were local
progression-free survival (LPFS) and enucleation-free
survival (EFS). Secondary endpoints were overall survival
(OS) and distant metastasis-free survival (DMFS), acute
and late treatment toxicity as well as visual acuity. LPFS
was considered to be the time from the last day of treat-
ment to local progression or death from any cause. Local
control (LC) was defined as the lack of tumor progres-
sion including all cases of stable disease, partial remis-
sion and complete remission. Complete remission was
defined as a disappearance of the tumor, partial remis-
sion as a decrease in the tumor volume > 30% and stable
disease when the tumor size did not change after the
therapy. EFS was defined as the time between the last
day of therapy and enucleation or death from any cause.
OS and DMFS were considered as the time period be-
tween the first diagnosis and death or appearance of dis-
tant metastasis. Survival analysis was performed using
the Kaplan-Meier method and the log–rank test.
The log-rank model was used to perform a univariate ana-
lysis after determining potentially prognostic factors for sur-
vival. WHO (World Health Organization) performance
status (0 vs. 1/2), age (median age of 65 years vs. > 65 years),
gender (male vs. female), tumor size (T1/2 vs. T3) and treat-
ment dose (median BED ≤100 Gy vs. > 100 Gy) were ana-
lyzed for their prognostic significance. A p-value ≤0.05 was
considered statistically significant. Due to the small number
of patients we abstained from a multivariate analysis.
Acute toxicity according to the Common Terminology
Criteria for Adverse Events (CTCAE) v4.03 was defined as a
toxicity occurring ≤3 months and chronic toxicity > 3 months
after the therapy.
Results
Patient characteristics
Twenty-four patients were identified and reviewed using
the National Center for Tumor Diseases (NCT) cancer
registry and the patients’ medical records. In 15 patients
the tumor was located in the right eye (62.5%) and in
nine patients in the left eye (37.5%). The patients’
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characteristics are shown in Table 1. Most patients were
initially staged as T2 (n = 5; 20.8%) or T3 (n = 14;
58.3%), N0 (n = 24; 100%) and M0 (n = 23; 95.8%). One
patient presented with distant metastases at first diagno-
sis (4.2%). Three patients could not be staged for T stage
due to missing data (12.5%). Mean age at the time of the
treatment was 63 years (range: 40–89 years). Gender
was equally distributed with 50% male and 50% female
patients. The majority of the patients had an excellent
WHO performance status of 0 (n = 14; 58.3%) and 1 at
the time of the first examination (n = 8; 33.3%).
Treatment characteristics
Twenty-two patients underwent primary treatment. The
treatment characteristics are depicted in Table 2. In two
patients, stereotactic fractionated photon RT was con-
ducted as re-irradiation (8.3%), in one patient after pri-
mary proton-beam RT (4.2%), in another patient after
primary BRT (4.2%).
The most frequently prescribed hypofractionated
dose regimes were 50 Gy in 5 Gy single dose fractions
(n = 9; 37.5%) and 70 Gy in 7 Gy single dose fractions
(n = 5; 20.8%). Other dose fractionations were 50 Gy in
2 Gy single dose fractions (n = 4; 16.7%), 75 Gy in 7.5 Gy
single dose fractions (n = 1; 4.2%), 55 Gy in 3 Gy single
dose fractions (n = 1; 4.2%), 25 Gy in 5 Gy single dose frac-
tions (n = 1; 4.2%) and 50 Gy in 10 Gy single dose fractions
(n = 1; 4.2%). Median total dose was 60 Gy corresponding to
a median BED of 78 Gy (range: 37.5–131.25 Gy). Median
follow up was 5.2 years.
Local progression-free survival
We observed a good local control rate, with a LPFS of
82% after 5 years (Fig. 1) and a median LPFS of 5.5 years.
Gender showed a significant impact on LPFS. We identi-
fied a 5-year LPFS of 100% for men and 73% for women
(log-rank: p = 0.04; Fig. 2). Hence, all local progressions
occurred in women (n = 4; 100%). Enucleation rate
(p = 0.804), age (p = 0.472), T stage (p = 0.517), time
period between the first diagnosis and the beginning
of radiotherapy (p = 0.535), BED (p = 0.839) as well
as performance status (p = 0.85) were not identified
as prognostic factors for LPFS in the univariate ana-
lysis. At the time of last assessment, complete re-
sponse could be observed in one patient (4.2%),
partial response in eight patients (33.3%), stable disease
in 11 patients (45.8%) and progressive disease in four
patients (16.7%). The overall response rate including
complete response, partial response and stable disease
was 86.4% (n = 20). Three of four progressions occurred
Table 1 Patient characteristics (n = 24)
Age
Median 66 years
Range 40–89 years
n %
Gender
Male 12 50.0
Female 12 50.0
WHO Performance Status
0 14 58.3
1 8 33.3
2 2 8.3
Tumor size
Tx 3 12.50
T1 2 8.30
T2 5 20.80
T3 14 58.30
Lymph node status
N0 24 100
N1 0 0
Distant metastases
M0 23 95.80
M1 1 4.20
Table 2 Stereotactic fractionated photon radiotherapy: Results
(n = 24)
Radiotherapy dose in BED
Median 78 Gy
Range 37.5–131.25 Gy
Follow up 5.2 years
n %
Linear accelerator-based fractionated photon radiotherapy
Primary irradiation 24 100
Re-irradiation 2 8.3
Local response
Complete remission 1 4.2
Partial remission 8 33.3
Stable disease 11 45.8
Progressive disease 4 16.7
Enucleation rate 5 20.9
Due to grade 4 toxicity 4 16.7
Due to recurrence 1 4.2
Eye conservation 19 79.1
Blindness before radiotherapy (n = 24) 4 16.7
Blindness after 24 months (n = 20)
Due to grade 4 toxicity 5 25.0
Due to recurrence 0 0
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within the first 5 years after therapy. All progressions
were diagnosed within the radiation field. Two patients
with locally progressive disease were treated with
re-irradiation, one patient with enucleation and another
patient with eye-preserving salvage surgery.
Enucleation-free survival
During follow-up, five patients underwent enucleation
and four of them were women (80.0%). The overall enu-
cleation rate was 21% with a 2-year and 5-year EFS of 88
and 83%, respectively (Fig. 3). All enucleations occurred
Fig. 1 Local progression-free survival in years
Fig. 2 Local progression-free survival dependent on gender. Gender has a significant impact on LPFS (p = 0.04)
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in patients who were irradiated with a BED ≥100 Gy and
had a higher T stage (T1/2 vs. 3). In the univariate ana-
lysis, we established a BED ≥100 Gy as a prognostic fac-
tor for worse EFS (p < 0.0001; Fig. 4). T stage showed no
significant impact on EFS (p = 0.069), but the curve pro-
gression suggests a negative influence of T3 stage on the
EFS (Fig. 5). Indeed, tumor size correlated significantly
with the enucleation rate (log-rank: p = 0.01). Importantly,
there was no correlation between local recurrence and
EFS (p = 0.823). Data of histopathological analysis of sec-
ondary enucleated eyes were available in three of five
cases. Only one enucleation was due to a locally recurrent
disease (4.2%) with 35 mitotic figures per 50 HPF identi-
fied. In fact, most enucleations were conducted due to side
Fig. 3 Enucleation-free survival in years
Fig. 4 Enucleation-free survival dependent on the BED. A BED ≥ 100 Gy has a significant worse impact on EFS (p < 0.0001)
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effects of radiotherapy (n = 4; 80%). In two cases, pro-
nounced necrosis could be identified histopathologically.
Overall and distant metastasis-free survival
Median overall survival (OS) was 5.75 years for all pa-
tients with a 2-year and 5-year OS rate of 100 and 70%,
respectively. Univariate analysis for prognostic factors
showed a significant impact of age (p = 0.046), local pro-
gression rate (p = 0.041), T-stage (p = 0.019) and time
between the initial diagnosis and the beginning of the
therapy (p = 0.01) on OS. A significantly lower 2-year
OS could be registered in patients who were older than
65 years (60% vs. 88%), had a T3 tumor (66% vs. 83% for
T1/2) or a local progression (50% vs. 76%) and who did
not started the treatment within 4 weeks after the initial
diagnosis (44% vs. 64%). Gender (p = 0.73), performance
status (p = 0.718), BED (p = 0.478) and the distant pro-
gression rate (p = 0.103) did not correlate with OS.
Distant metastases developed in seven patients (29%),
five within the first 5 years after the initial diagnosis
(20.8%). Metastases involved the liver in one case (4%),
the brain in one case (4%), the liver and the lungs in
three cases (13%), the liver, the lungs and the brain in
one case (4%) and cervical lymph nodes in one case
(4%). Six of seven patients received palliative systemic
therapy including Sorafenib (n = 1, 4%), Interferon
(n = 1, 4%), Gemcitabine (n = 1, 4%), Gemcitabine/
Treosulfam (n = 1, 4%) and Dacarbazin, Vindesin and
Cisplatin (n = 2, 8%). All patients with metastatic
disease and palliative systemic therapy died after a
median time of 12 months after first diagnosis of the
metastases. One patient received systemic unilateral
neck dissection for lymph node metastases and was
still alive at last follow up. 2-year and 5-year DMFS
were 90 and 59%, respectively. In the univariate ana-
lysis, we identified a statistically significant negative
impact of T3 stage (p = 0.027), local progression rate
(p = 0.038) and time between initial diagnosis and beginning
of radiotherapy > 4 weeks (p = 0.004) on DMFS. Perform-
ance status (p = 0.850), gender (p = 0.670), age (p = 0.076)
and BED (p = 0.526) did not statistically significantly correl-
ate with DMFS.
Toxicity and visual acuity
Acute toxicity during and 3 months after radiotherapy was
assessed in all patients (n = 24). The therapy was tolerated
well with no grade 4 acute toxicities according to CTCAE
v4.03. Thirteen patients did not develop any acute side ef-
fects (54%). Among all patients, mild unilateral conjunctiv-
itis occurred in seven patients (29%) and was the most
frequent acute toxicity. Skin reaction with erythema and
edema was recorded in four patients (17%), of whom two
patients had a grade 1 (8.3%), one patient a grade 2 (4.2%)
and another patient a grade 3 acute skin reaction (4.2%).
We had to exclude three patients from the analysis of
late toxicities because of incomplete medical records
(12.5%). Chronic radiogenic side effects occurred in 12
patients (57.1%); in six cases within the first year (28.6%)
and in two cases within 2 years after therapy (9.5%).
Long term adverse side effects occurred in four patients
(19.0%). Within the first 6 months after therapy, we
identified a grade 1 macula edema in two patients
(9.5%), and slight sicca symptoms in another patient
(4.7%). One year after therapy, one patient developed a
Fig. 5 Enucleation-free survival dependent on T stage. T3 stage has a negative impact on EFS (p = 0.069)
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grade 2 toxicity with cloudiness of the lens and a slight
visual restriction (4.7%). A grade 3 ischemic retinopathy
with vision restriction occurred in two patients after two
and 12 years (9.5%), a grade 3 glaucoma in one patient
8 years after therapy (4.7%). During follow up, six
patients suffered from a grade 4 retinopathy with conse-
quential blindness (25%). Four patients received an enucle-
ation due to central artery obliteration, retinal detachment,
recurrent painful corneal ulcer or vitreous hemorrhage
after a mean time of 2 years after irradiation (19.0%). Two
patients went blind because of retinal detachment without
enucleation, both nearly 1 year post therapy (9.5%).
We measured optic nerve damage indirectly with the
preservation of sight within 24 months after therapy.
We excluded ten patients from the analysis (41.7%) who
were initially blind (n = 4; 16.7%), became blind because
of other treatment-related side effects (n = 5; 20.8%) or
had a tumor recurrence in this time period (n = 1; 4.2%).
Initially, four patients suffered from tumor caused blind-
ness (16.7%) and 20 patients had visus restrictions
(83.3%). Visus was measured by an ophthalmologist at
the beginning of the therapy and 3 months, 6 months,
12 months and 24 months after therapy. We systematic-
ally analyzed the records of the remaining 14 patients
(62.5%). We defined a visus loss over 1/3 compared to
the initially measured visus as visual impairment, a visus
increase over 1/3 as improved visual acuity and all other
results as stable visus. Six weeks after therapy, 11 pa-
tients had a stable visus (73.3%), two patients showed an
improvement of the initial visus (13.3%) and one patient
had a visual impairment (6.7%). Within 6 and 12 months,
two more patients developed a visual impairment (over-
all n = 3; 20%). Five patients with visual impairment
(35.7%), four patients with stable visus (28.6%) and five pa-
tients with visual acuity (35.7%) could be identified within
24 months after therapy. No blindness due to optic nerve
atrophy occurred in this time period. Therefore, we identi-
fied a 2-year sight-conservation rate of 75%.
Discussion
In the 1970s, enucleation was considered as the only ther-
apy option in the treatment of uveal melanomas. In 1998,
the COMS, a prospective trial, compared two therapy mo-
dalities, enucleation and BRT. Large tumors with more
than 18 mm in diameter and 8 mm in height were ex-
cluded from the analyses. The authors could demonstrate
an equal 5-year survival rate of 81% for both therapy op-
tions. Thus, BRT was established as an eye-preserving
treatment for small and medium sized uveal melanomas
[3–5]. Nowadays, the therapy standard consists of plaque
brachytherapy and charged particle therapy with protons
[10, 11]. Additionally, other treatment modalities like
stereotactic radiosurgery with gammaknife or cyberknife
as well as stereotactic fractionated photon radiotherapy
gain in importance [6, 12–14]. Prospective studies com-
paring external beam RT and BRT are still missing. In the
current study, we analyzed 24 patients treated with stereo-
tactic photon beam RT. In contrast to the COMS, we
treated a great number of large sized tumors. However, we
assessed adequate survival rates with a five-year OS, LRFS
and DMFS of 70, 82 and 59%, respectively. Although ap-
plied doses vary widely for SRS /FSRT, 5-year OS between
60 and 90%, LC between 87 and 97% as well as eye reten-
tion rates between 77 and 90% are described in the
current literature [14–16].
Nowadays, enucleation is only used in recurrent dis-
ease of medium sized melanomas or in large tumors
without the option of other eye-preserving therapies. In
our analyses, a 5-year eye-preservation was achieved in
83% and a 2-year preservation of the visual acuity in
75% of the patients. The overall enucleation rate was
20.8%. In the current literature, the eye preservation rate
fluctuates between 72 and 97% after BRT and between
76 and 89% for charged particles [17–24]. Verschueren
et al. identified an eye-preservation rate of 96% for BRT
in the treatment of small and intermediate sized tumors
[20]. In their analyses, visual acuity was preserved in
52%. In a comparable trial by Yazici et al. the authors
identified a 5-year eye-preservation rate of 73% for
LINAC based SRS/FSRT with 1–3 fractions conducted
via cyberknife [12]. Furdova et al. could even show an
eye-retention rate of 88% after one step LINAC based
SRS with a single dose fraction of 35 Gy for T2 or T3
uveal melanoma [25]. Generally, outcome of long term
visual acuity is poor after RT. Gragoudas et al. reported
a decreased visual acuity < 0.1 Snellen 5 years after pro-
ton beam RT [26]. Modorati et al. described a high rate
of visual loss after follow up for gamma knife radiosur-
gery [15]. During the first 2 years after RT, visual acuity
decreased in none of our patients. Stereotactic photon
RT in the treatment of large uveal melanomas seems to
be an effective method for eye and visual preservation.
Furthermore, we identified prognostic factors for OS,
LPFS, DMFS and EFS. Gender had a significant impact
on LPFS with higher tumor progression rates for
women. T stage was the strongest prognostic factor in
the univariate analysis and had an impact on the OS,
DMFS and the EFS. Although tumor size could not be
identified as independent prognostic factor on EFS, we
could show a significant impact of T stage on the enu-
cleation rate, possibly due to the small number of pa-
tients analyzed in the current study. In accordance,
Bensoussan et al. described a five-year OS for T3 stage
vs. T4 stage of 68% vs. 52% [27]. Several other authors
reported higher tumor size resulting in higher enucle-
ation rate [23, 28–30]. Furthermore, we showed a nega-
tive influence of a BED > 100 Gy on the EFS especially
due to negative side effects of the therapy. Whether
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higher enucleation rate is directly linked to higher pre-
scribed doses or depends more on higher T stage as well
as larger RT field with consequently higher doses to the
critical organs still remains unclear.
Nevertheless, it is known that nearly 20% of all irradi-
ated patients suffer under enucleation after therapy and
that a considerable proportion is caused by side effects.
For good local control, high doses are necessary. Fur-
dova et al. reported a 5-year local control rate of 85%
while secondary enucleation due to complications like
treatment-related neuropthy and secondary glaucoma
was necessary in 12% of the patients after single dose
SRS with 35 Gy [25]. Dieckmann et al. reported a good
local control rate of 98% and enucleation rate of 7.7%
when a dose between 50 Gy and 60 Gy in 5 Gy single
dose was applied according a BED between 75 Gy and
90 Gy. Nevertheless, retinopathy, cataract and optic
nerve damage occurred in 25.5, 18.9% and in 20% of the
patients [13]. Other studies described similar results in
the local control rate with 2-year and 5-year local con-
trol rates of 100 and 96% and no enucleations when only
50 Gy was applied on the tumor in 5 Gy single dose
fractions corresponding a BED of 75 Gy [31]. Dose
optimization is necessary for achieving good local con-
trol rates and adequate preservation of the organs at risk
to provide high enucleation rates. Gragoudas et al. could
not show a benefit for visual acuity when radiotherapy
dose was reduced from 70 Gy to 50 Gy for protons [32].
In the current analysis 80% of the enucleations (overall
20.8%) were caused by grade 4 toxicities. Bensoussan et al.
reported a similar enucleation rate of 19.5% for large tu-
mors which were treated with BRT, the majority due to
negative side effects [27]. In the current study 2-year and
the 5-year chronic toxicity rates of 38 and 57% could be
identified. A meta-analysis by Wang et al. showed equal
enucleation rates and survival rates for charged particle
radiotherapy in the treatment of uveal melanomas com-
pared with stereotactic photon radiotherapy and BRT
[10]. The authors found a significantly lower toxicity
rate of cataract formation and radiation-induced ret-
inopathy. Thus, particle therapy is used in large mela-
nomas with paripapillary location for better organ at
risk conservation. However, in recent years, hypofrac-
tionated stereotactic radiotherapy has been shown to
be an effective alternative to protons [13, 31, 33]. Al-
though data with larger case series are available now-
adays, e.g. by Yazici et al. and by van den Bosch et
al., prospective studies are still lacking [12, 28].
Nevertheless, the current data situation regarding the
effect of FSRT on EFS with adequate follow-up times
to assess long-time effects of therapy is thin. There-
fore, we think that the current study could strengthen
prior results despite its retrospective character, small
number of patients and various RT schedules applied.
Conclusions
Stereotactic hypofractionated RT is a safe alternative to
surgical eye enucleation in uveal melanoma patients,
yielding good local control rates as well as allowing eye-
sight preservation and avoidance of surgery in the ma-
jority of patients.
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